Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Radiation Therapy in ES-SCLC Maintenance
NCT06350162Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in small cell lung cancer (SCLC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: 1-year Progression-free survival rate. Started Oct 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06350162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06350162.